JPWO2020059772A1 - 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 - Google Patents

抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 Download PDF

Info

Publication number
JPWO2020059772A1
JPWO2020059772A1 JP2020548575A JP2020548575A JPWO2020059772A1 JP WO2020059772 A1 JPWO2020059772 A1 JP WO2020059772A1 JP 2020548575 A JP2020548575 A JP 2020548575A JP 2020548575 A JP2020548575 A JP 2020548575A JP WO2020059772 A1 JPWO2020059772 A1 JP WO2020059772A1
Authority
JP
Japan
Prior art keywords
her3
cancer
antibody
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020548575A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020059772A5 (https=
Inventor
久美子 小山
久美子 小山
能伸 塩瀬
能伸 塩瀬
傑 上野
傑 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JPWO2020059772A1 publication Critical patent/JPWO2020059772A1/ja
Publication of JPWO2020059772A5 publication Critical patent/JPWO2020059772A5/ja
Priority to JP2024086183A priority Critical patent/JP2024109885A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020548575A 2018-09-20 2019-09-19 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 Pending JPWO2020059772A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086183A JP2024109885A (ja) 2018-09-20 2024-05-28 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018175510 2018-09-20
JP2018175510 2018-09-20
PCT/JP2019/036668 WO2020059772A1 (ja) 2018-09-20 2019-09-19 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086183A Division JP2024109885A (ja) 2018-09-20 2024-05-28 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療

Publications (2)

Publication Number Publication Date
JPWO2020059772A1 true JPWO2020059772A1 (ja) 2021-08-30
JPWO2020059772A5 JPWO2020059772A5 (https=) 2022-09-16

Family

ID=69887630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548575A Pending JPWO2020059772A1 (ja) 2018-09-20 2019-09-19 抗ｈｅｒ３抗体−薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
JP2024086183A Pending JP2024109885A (ja) 2018-09-20 2024-05-28 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086183A Pending JP2024109885A (ja) 2018-09-20 2024-05-28 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療

Country Status (7)

Country Link
US (1) US12527979B2 (https=)
EP (1) EP3854418A4 (https=)
JP (2) JPWO2020059772A1 (https=)
KR (1) KR20210062005A (https=)
CN (1) CN112912109A (https=)
BR (1) BR112021005246A2 (https=)
WO (1) WO2020059772A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021289927A1 (en) * 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
JP7847132B2 (ja) * 2020-10-14 2026-04-16 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｈｅｒ３抗体と抗ｈｅｒ３抗体薬物複合体及びその医薬用途
WO2022099762A1 (zh) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 一种抗体偶联物中间体及其制备方法
JP2024533356A (ja) * 2021-09-16 2024-09-12 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 抗ｈｅｒ３抗体薬物複合体及びその組成物並びに用途
TW202341984A (zh) * 2022-01-28 2023-11-01 大陸商映恩生物製藥（蘇州）有限公司 Ｈｅｒ３抗體藥物偶聯物及其用途
CN119212732A (zh) * 2022-04-29 2024-12-27 四川科伦博泰生物医药股份有限公司 抗体药物缀合物及其制备方法和用途
WO2024147097A1 (en) * 2023-01-03 2024-07-11 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
CN119139488A (zh) * 2023-06-15 2024-12-17 信达生物制药(苏州)有限公司 包含靶向Claudin18.2的抗体-药物偶联物的制剂及其制备方法和用途
CN121752297A (zh) * 2023-09-01 2026-03-27 四川科伦博泰生物医药股份有限公司 抗体-药物缀合物及其制备方法和用途
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025108438A1 (zh) * 2023-11-24 2025-05-30 江苏恒瑞医药股份有限公司 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法
WO2025248072A1 (en) * 2024-05-30 2025-12-04 BioNTech SE Use of anti-her3 antibody-drug conjugates in cancer treatment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500638A (ja) * 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2015536336A (ja) * 2012-11-08 2015-12-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ４のベータヘアピンに結合する抗ｈｅｒ３／ｈｅｒ４抗原結合タンパク質
JP2017503784A (ja) * 2014-04-10 2017-02-02 第一三共株式会社 抗ｈｅｒ３抗体−薬物コンジュゲート
JP2017521050A (ja) * 2014-05-14 2017-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピンに結合する抗ｈｅｒ３抗体
JP2018516870A (ja) * 2015-04-24 2018-06-28 メリマック ファーマシューティカルズ インコーポレーティッド ３つの完全ヒトモノクローナル抗ｅｇｆｒ抗体の組み合わせを用いて上皮成長因子受容体（ｅｇｆｒ）の細胞外ドメインに変異を有する患者を治療する方法
JP2018522822A (ja) * 2015-05-20 2018-08-16 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
WO2018159582A1 (ja) * 2017-02-28 2018-09-07 学校法人近畿大学 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6774116B2 (en) 2001-04-17 2004-08-10 Cryolife, Inc. Prodrugs via acylation with cinnamate
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
WO2006135371A1 (en) 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
EP2069308B1 (en) 2006-09-12 2017-03-29 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Azonafide derived tumor and cancer targeting compounds
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Ｅｒｂｂ3에 대한 항체 및 이의 용도
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
AU2010306774A1 (en) 2009-10-14 2012-05-03 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof
MX343227B (es) 2010-04-09 2016-10-28 Aveo Pharmaceuticals Inc Anticuerpos anti-erbb3.
CA2795349C (en) 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
WO2012064733A2 (en) 2010-11-09 2012-05-18 Medimmune, Llc Antibody scaffold for homogenous conjugation
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
IN2014DN06806A (https=) 2012-02-10 2015-05-22 Univ Maryland
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2014134457A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
US10516432B2 (en) * 2016-12-01 2019-12-24 Mediatek Inc. Communication system with switchable devices
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500638A (ja) * 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
JP2015536336A (ja) * 2012-11-08 2015-12-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピン及びｈｅｒ４のベータヘアピンに結合する抗ｈｅｒ３／ｈｅｒ４抗原結合タンパク質
JP2017503784A (ja) * 2014-04-10 2017-02-02 第一三共株式会社 抗ｈｅｒ３抗体−薬物コンジュゲート
JP2017521050A (ja) * 2014-05-14 2017-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ３のベータヘアピンに結合する抗ｈｅｒ３抗体
JP2018516870A (ja) * 2015-04-24 2018-06-28 メリマック ファーマシューティカルズ インコーポレーティッド ３つの完全ヒトモノクローナル抗ｅｇｆｒ抗体の組み合わせを用いて上皮成長因子受容体（ｅｇｆｒ）の細胞外ドメインに変異を有する患者を治療する方法
JP2018522822A (ja) * 2015-05-20 2018-08-16 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
WO2018159582A1 (ja) * 2017-02-28 2018-09-07 学校法人近畿大学 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
第一三共株式会社, ＤＳ−８２０１の非小細胞肺がん患者を対象とした第２相試験の開始について, 第一三共株, JPN7019003722, ISSN: 0005356891 *

Also Published As

Publication number Publication date
EP3854418A4 (en) 2022-07-27
CA3113207A1 (en) 2020-03-26
JP2024109885A (ja) 2024-08-14
US20220072144A1 (en) 2022-03-10
EP3854418A1 (en) 2021-07-28
US12527979B2 (en) 2026-01-20
TW202024133A (zh) 2020-07-01
WO2020059772A1 (ja) 2020-03-26
CN112912109A (zh) 2021-06-04
BR112021005246A2 (pt) 2021-06-15
KR20210062005A (ko) 2021-05-28

Similar Documents

Publication Publication Date Title
US12527979B2 (en) Treatment of HER3-mutated cancer by administration of anti-HER3 antibody-drug conjugate
US20220023436A1 (en) Combination of antibody-drug conjugate with parp inhibitor
WO2022102695A1 (ja) 抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療
WO2020031936A1 (ja) 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
WO2018159582A1 (ja) 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法
US20210290777A1 (en) Treatment of metastatic brain tumor by administration of antibody-drug conjugate
JPWO2019230645A1 (ja) 抗ｈｅｒ２抗体−薬物コンジュゲート投与によるｈｅｒ２変異がんの治療
EP4245321A1 (en) Combination of antibody-drug conjugate with anti-sirpalpha antibody
US20260091123A1 (en) Combination of anti-b7-h3 antibody-drug conjugate and atr inhibitor or atm inhibitor
JP7325045B2 (ja) 癌を処置する抗体コンストラクトおよび方法
TWI920018B (zh) 抗ｈｅｒ３抗體-藥物結合物用於治療ｈｅｒ３突變癌之醫藥的用途
CA3113207C (en) Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
JP7848119B2 (ja) 抗ｈｅｒ２抗体－薬物コンジュゲートとｈｅｒ二量体化阻害剤の組み合わせ
HK40046216A (en) Treatment of her3 mutant cancer by administration of anti-her3 antibody-drug conjugate
CA3101906C (en) Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate
HK40086585A (en) Combination of (anti-her2 antibody)-drug conjugate and her dimerization inhibitor
HK40093327A (en) Combination of antibody-drug conjugate with anti-sirpalpha antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240229

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240605

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240628

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306